Skip to main content

Table 2 Descriptive statistics for the QLQ-BN20

From: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran

   Number of forms Mean (SD) Floor N (%) Ceiling (%) Cronbach’s alpha Normality (Kolmogoroff-Smirnoff-Test)
BFU (future uncertainty) Baseline 194 39.9 (24.9) 8 (4.1%) 3 (1.5%) 0.80 0.14
Follow-up 187 36.8 (24.5) 10 (5.3%) 3 (1.6%) 0.74 0.24
BVD (visual disorder) Baseline 194 27.9 (26.9) 17 (8.7%) 5 (2.6%) 0.74 0.16
Follow-up 187 25.8 (25.9) 14 (7.4%) 4 (2.1%) 0.80 0.15
BMD (motor dysfunction) Baseline 194 29.0 (28.9) 28 (14.4%) 6 (3.1%) 0.80 0.46
Follow-up 186 28.6 (29.6) 23 (12.3%) 3 (1.6%) 0.82 0.18
BCD (communication deficit) Baseline 194 23.7 (27.2) 18 (9.2%) 3 (1.5%) 0.89 0.21
BHA (headaches) Follow-up 187 20.9 (25.0) 14 (7.5%) 1 (0.5%) 0.89 0.22
Baseline 192 46.9 (33.9) 25 (13.0%) 24 (12.5%) - 0.19
Follow-up 187 43.6 (35.1) 21 (11.2%) 18 (9.6%) - 0.15
BSE (seizures) Baseline 194 10.0 (21.6) 99 (51.5%) 7 (3.6%) - 0.13
Follow-up 186 7.7 (20.0) 95 (51.0%) 1 (0.5%) - 0.11
BDR (drowsiness) Baseline 192 32.2 (31.7) 28 (14.6%) 11 (5.7%) - 0.6
Follow-up 185 31.2 (32.0) 19 (10.3%) 8 (4.3%) - 0.5
BHL (hair loss) Baseline 194 23.8 (32.5) 41 (21.1%) 9 (4.6%) - 0.28
Follow-up 187 25.9 (44.4) 38 (20.3%) 10 (5.3%) - 0.06
BIS (itchy skin) Baseline 193 14.0 (25.8) 54 (28.0%) 5 (2.6%) - 0.20
Follow-up 186 17.8 (27.5) 46 (24.7%) 6 (3.2%) - 0.32
BWL (weakness of legs) Baseline 190 28.4 (33.9) 23 (12.1%) 14 (7.4%) - 0.36
BBC (bladder control) Follow-up 187 28.3 (34.1) 21 (11.2%) 12 (6.4%) - 0.29
Baseline 194 15.1 (25.8) 67 (34.5%) 4 (2.0%) - 0.20
Follow-up 186 15.2 (30.3) 58 (31.2%) 6 (3.2%) - 0.30